...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.
【24h】

Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.

机译:罗红霉素通过抑制VEGF的产生在体内抑制人肝癌细胞的血管生成。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Recently, 14-member macrolide antibiotics such as Clarithromycin and Roxithromycin (RXM) have been shown to have anti-cancer and anti-angiogeneic effects. However, it is not fully understood whether and how RXM suppresses angiogenesis in human hepatoma, which is a well-known hypervascular tumor. MATERIALS AND METHODS: In the present study, we examined the effects of RXM on tumor angiogenesis in the human hepatoma cell line, HepG2. In vivo, angiogenesis was examined using a mouse dorsal air sac model. RESULTS: The inhibitory effect of RXM was dose-dependent and the angiogenesis index of 100mg/kg/day of RXM administered intraperitoneally twice a day was significantly lower than the control. Next, we examined the effect of RXM on vascular endothelial growth factor (VEGF) mRNA expression and its protein level in HepG2 cells. When 100 microM of RXM were added, VEGF mRNA expression in HepG cells was inhibited and its protein level reduced. CONCLUSION: These results suggest that RXM inhibits tumorangiogenesis in human hepatoma, and that VEGF alteration may be involved in the mechanism of this inhibitory effect. Because RXM is widely used in clinical practice, it may represent an effective new strategy for human hepatoma therapy.
机译:背景:最近,已显示14个成员的大环内酯类抗生素,如克拉霉素和罗红霉素(RXM)具有抗癌和抗血管生成作用。然而,尚未完全了解RXM是否以及如何抑制人肝癌(一种众所周知的高血管肿瘤)中的血管生成。材料与方法:在本研究中,我们研究了RXM对人肝癌细胞HepG2肿瘤血管生成的影响。在体内,使用小鼠背囊模型检查血管生成。结果:RXM的抑制作用是剂量依赖性的,每天两次腹膜内给药的RXM的血管生成指数100mg / kg /天明显低于对照组。接下来,我们检查了RXM对HepG2细胞中血管内皮生长因子(VEGF)mRNA表达及其蛋白水平的影响。当添加100 microM RXM时,HepG细胞中的VEGF mRNA表达受到抑制,其蛋白水平降低。结论:这些结果表明RXM抑制人肝癌的肿瘤血管生成,而VEGF的改变可能与这种抑制作用的机制有关。由于RXM在临床实践中被广泛使用,它可能代表了人类肝癌治疗的有效新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号